The NNRTI efavirenz has long been one of the most frequently employed antiretroviral drugs
in the multidrug regimens used to treat HIV infection, in accordance with its well …

Antiretroviral drugs are associated with a variety of adverse effects on the central and
peripheral nervous systems. The frequency and severity of neuropsychiatric adverse events …

Background Use of raltegravir with optimum background therapy is effective and well
tolerated in treatment-experienced patients with multidrug-resistant HIV-1 infection. We …

Neurocognitive (NC) complications continue to afflict a substantial proportion of HIV-infected
people taking effective antiretroviral therapy (ART). One contributing mechanism for this is …

Suicide has long been associated with serious illness generally and HIV specifically. New
treatments have affected prognosis in HIV positively, but it is unclear how they impact on …

Objectives: To determine the influence of cytochrome P450 2B6 (CYP2B6) genotype on the
rate of oxidative efavirenz metabolism in human liver microsomes. Materials & methods …

BACKGROUND AND PURPOSE Efavirenz (EFV) is widely used in the treatment of HIV‐1
infection. Though highly efficient, there is growing concern about EFV‐related side effects …

In patients infected by HIV, the efficacy of highly active antiretroviral (ARV) therapy through
the blockade of different steps of the retrovirus life cycle is now well established. As HIV is a …

Efavirenz (EFV) is a non‐nucleoside reverse transcriptase inhibitor (NNRTI) widely used in
human immunodeficiency virus (HIV) infection therapy. It has been associated with …

The implementation of combined antiretroviral therapy (cART) significantly reduces the
mortality associated with human immunodeficiency virus (HIV) infection. However …